The global migraine market witnesses rising growth. The continual growth attributes to the increasing prevalence of the condition worldwide. The pain and symptoms associated with this debilitating and recurrent, chronic neurologic disease severely impact the quality of life of sufferers. Chronic migraine disorder can result in extruding pain and sleep-less nights, further leading to various health complications. The migraine market is a well-developed space with the availability of many novel medicines and therapies to treat symptoms of the condition.
The availability of various innovative, effective treatments is a key driving force influencing market growth significantly. According to Market Research Future (MRFR), the Migraine Market is projected to reach USD 2.2 billion by 2030 at CAGR of 3.10% during the forecast period 2022-2030. In its recently published market forecast, MRFR also asserts that the market would grow at a moderate CAGR throughout the forecast period (2022– 2030). The availability of therapeutic medicines is fuelling market growth, providing growth opportunities to the market.
Major Players:
The Migraine market Players are Impax Laboratories, Allergan, Abbott Laboratories, Inc., Eli Lilly and Company, Eisai Inc., Pfizer, Inc., Klaria, Johnson & Johnson, Kowa Pharmaceuticals America, Meda, Merck, Luitpold Pharmaceuticals, OptiNose, GlaxoSmithKline plc, and AstraZeneca plc, among others.
Global Migraine Market - Regional Analysis
North America heads the largest migraine meda market share. Favourable reimbursement scenarios and high healthcare expenditures are key driving forces behind the regional market growth. Also, the wide uptake of new technologies in the treatment of migraines drives the growth of the market substantially. The US, heading with its well-developed Migraine treatment market, accounts for the largest share in the regional market.
Europe stands the second-leading position in the global Migraine market. The increasing prevalence of the condition drives market growth. Besides, the resurging economy acts as a tailwind to the regional market growth, availing many novel treatments and drugs. The European Migraine treatment market is expected to grow at a considerable CAGR.
The Asia Pacific Migraine market is estimated to emerge as the fastest-growing market from 2018 to 2023. China and India predominantly lead the APAC migraine market, heading with the vast population and the availability of cost-competitive therapeutics.
Global Migraine Market – Segmentations
The report is segmented into four market dynamics to widen the scope of understanding,
By Types: Episodic and Chronic.
By Treatment Type: Preventive and Abortive.
By Drug Class: Triptans and Ergots, among others.
By Regions: Asia Pacific, North America, Europe, and the Rest-of-the-World.
Global Migraine Market - Competitive Analysis
The Migraine market research report appears to be fiercely competitive and fragmented due to the presence of several well-established players. They alongside, the new entrants, form a completive landscape in the market. They incorporate strategic initiatives such as collaboration, mergers & acquisitions, expansion, and technology launch. Substantial investments are transpired in clinical trials and the development of effective drugs.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.